SCHEMBL3070514

SCHEMBL3070514

CCOC(=O)c1cccc(OCC(OCC)OCC)c1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
ADRB2 P07550 1/20 0.48
ADRB1 P08588 1/20 0.48
ADRB3 P13945 1/20 0.48
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 3/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CYP4F2 P78329 1/20 0.47
CYP4A11 Q02928 1/20 0.47
F10 P00742 2/20 0.46
F2 P00734 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18685480 0.86 TDP1 (0.49) TDP1L3MBTL1ADRB2ADRB1ADRB3
SCHEMBL930302 0.86 NR1H4 (0.54) TDP1L3MBTL1ADRB2ADRB1ADRB3
SCHEMBL3065476 0.86 KMT2A (0.61) KMT2ASMN1; SMN2
SCHEMBL1989713 0.84 KMT2A (0.62) TDP1L3MBTL1KMT2AMEN1POLB
SCHEMBL5665404 0.83 SMN1; SMN2 (0.55) ADRB2ADRB1ADRB3KMT2AMEN1
SCHEMBL24141585 0.82 ADRB2 (0.49) TDP1L3MBTL1ADRB2ADRB1ADRB3
SCHEMBL13635033 0.81 TDP1 (0.44) TDP1L3MBTL1ADRB2ADRB1ADRB3
SCHEMBL4520513 0.81 LMNA (0.53) TDP1L3MBTL1KMT2AMAPTNPC1
SCHEMBL8703734 0.81 ADRB2 (0.49) TDP1L3MBTL1ADRB2ADRB1ADRB3
SCHEMBL7095551 0.80 ADRB2 (0.56) TDP1L3MBTL1ADRB2ADRB1ADRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3848380-A1 LABELLED NUCLEOTIDES Illumina Cambridge Limited (GB) 2021-07-14 EP disclosed
EP-3848380-A1 LABELLED NUCLEOTIDES Illumina Cambridge Limited (GB) 2021-07-14 EP disclosed
US-11028115-B2 Labelled nucleotides ILLUMINA CAMBRIDGE LIMITED (GB) 2021-06-08 US disclosed
US-11028116-B2 Labelled nucleotides ILLUMINA CAMBRIDGE LIMITED (GB) 2021-06-08 US disclosed
US-11028116-B2 Labelled nucleotides ILLUMINA CAMBRIDGE LIMITED (GB) 2021-06-08 US disclosed
US-11028115-B2 Labelled nucleotides ILLUMINA CAMBRIDGE LIMITED (GB) 2021-06-08 US disclosed
US-11008359-B2 Labelled nucleotides ILLUMINA CAMBRIDGE LIMITED (GB) 2021-05-18 US disclosed
US-11008359-B2 Labelled nucleotides ILLUMINA CAMBRIDGE LIMITED (GB) 2021-05-18 US disclosed
US-10995111-B2 Labelled nucleotides ILLUMINA CAMBRIDGE LIMITED (GB) 2021-05-04 US disclosed
US-10995111-B2 Labelled nucleotides ILLUMINA CAMBRIDGE LIMITED (GB) 2021-05-04 US disclosed
EP-1560838-B1 LABELLED NUCLEOTIDES ILLUMINA CAMBRIDGE LTD (GB) 2009-05-13 EP disclosed
US-20090062145-A1 Labelled nucleotides ILLUMINA CAMBRIDGE LIMITED (GB) 2009-03-05 US disclosed
US-20090062145-A1 Labelled nucleotides ILLUMINA CAMBRIDGE LIMITED (GB) 2009-03-05 US disclosed
US-20090062145-A1 Labelled nucleotides ILLUMINA CAMBRIDGE LIMITED (GB) 2009-03-05 US disclosed
US-7414116-B2 certain linkers connecting nucleotide bases to detachable labels (fluorophores) are cleaved using water soluble phosphines transition metal catalysts; sequencing; used in nick translation, random primer labeling, end-labeling (terminal deoxynucleotidyltransferase), reverse transcription, amplification ILLUMINA CAMBRIDGE LIMITED (GB) 2008-08-19 US disclosed
US-7414116-B2 certain linkers connecting nucleotide bases to detachable labels (fluorophores) are cleaved using water soluble phosphines transition metal catalysts; sequencing; used in nick translation, random primer labeling, end-labeling (terminal deoxynucleotidyltransferase), reverse transcription, amplification ILLUMINA CAMBRIDGE LIMITED (GB) 2008-08-19 US disclosed
US-7414116-B2 certain linkers connecting nucleotide bases to detachable labels (fluorophores) are cleaved using water soluble phosphines transition metal catalysts; sequencing; used in nick translation, random primer labeling, end-labeling (terminal deoxynucleotidyltransferase), reverse transcription, amplification ILLUMINA CAMBRIDGE LIMITED (GB) 2008-08-19 US disclosed
US-20060160081-A1 certain linkers connecting nucleotide bases to detachable labels (fluorophores) are cleaved using water soluble phosphines transition metal catalysts; sequencing; used in nick translation, random primer labeling, end-labeling (terminal deoxynucleotidyltransferase), reverse transcription, amplification ILLUMINA CAMBRIDGE LIMITED (GB) 2006-07-20 US disclosed
EP-1560838-A1 LABELLED NUCLEOTIDES Solexa Limited (GB) 2005-08-10 EP disclosed
WO-2004018493-A1 LABELLED NUCLEOTIDES SOLEXA LIMITED (GB) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160081-A1 certain linkers connecting nucleotide bases to detachable labels (fluorophores) are cleaved using water soluble phosphines transition metal catalysts; sequencing; used in nick translation, random primer labeling, end-labeling (terminal deoxynucleotidyltransferase), reverse transcription, amplification RNGTT, DNTT, POLQ TDP1 536/4885L3MBTL1 1287/4885ADRB2 4882/4885
US-11008359-B2 Labelled nucleotides NUDT1, DUT, NT5C2 TDP1 546/4885L3MBTL1 1632/4885ADRB2 4345/4885
US-10995111-B2 Labelled nucleotides NUDT1, DUT, NT5C2 TDP1 546/4885L3MBTL1 1632/4885ADRB2 4345/4885
US-11028116-B2 Labelled nucleotides NUDT1, DUT, NT5C2 TDP1 546/4885L3MBTL1 1632/4885ADRB2 4345/4885
US-11028115-B2 Labelled nucleotides NUDT1, DUT, NT5C2 TDP1 546/4885L3MBTL1 1632/4885ADRB2 4345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.